(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Unusual 'ingredients' helped stars form in a galaxy near the Milky Way - 2Can a mammogram help identify heart disease?
- 3Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- 4The moon and sun figure big in the new year's lineup of cosmic wonders
- 5Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- Russia provided Iran with list of Israeli energy targets, Ukrainian intelligence finds
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- Surveys of Thrillers That Re-imagined the Class
- Whale stranded off Germany for days found stuck again
- As nations push for more ambition at climate talks, chairman says they may get it
- Cameroon says Russia has confirmed 16 Cameroonian soldiers died in Ukraine
- Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem
- CNN Crew Detained and Journalist Put in Chokehold in IDF Run-In: ‘We’re Journalists. What Are You Doing?!’
- A Manual for the Right SUV for Seniors
